Immuneering Corporation
Immuneering Corporation (IMRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IMRX · as of Sep 30, 2025
Ownership Breakdown
69
Institutional Holders
▲ 30 vs Q2
$182.65M
Total Inst. Value
▲ $169.74M vs Q2
36.30M
Shares Outstanding
freeFloat 69.50%
26.09M
13F Shares Held
▲ 22.26M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IMRX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 8.79M | 24.42% | 24.42% | $61.51B | Nov 13, 2025 | ▲ 8.57M |
SANOFI pharmaceutical preparations | 2.71M | 7.53% | 7.53% | $18.96B | Nov 4, 2025 | NEW |
VANGUARD GROUP INC pharmaceutical preparations | 2.42M | 6.71% | 6.71% | $16.91B | Nov 7, 2025 | ▲ 1.36M |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 1.80M | 5.00% | 5.00% | $12.59B | Nov 14, 2025 | ▲ 1.80M |
EXODUSPOINT CAPITAL MANAGEMENT, LP pharmaceutical preparations | 1.52M | 4.22% | 4.22% | $10.62B | Nov 14, 2025 | NEW |
LOGOS GLOBAL MANAGEMENT LP pharmaceutical preparations | 950.0K | 2.64% | 2.64% | $6.65B | Nov 14, 2025 | NEW |
CITADEL ADVISORS LLC pharmaceutical preparations | 943.1K | 2.62% | 2.62% | $6.60B | Nov 14, 2025 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 681.2K | 1.89% | 1.89% | $4.77B | Nov 12, 2025 | ▲ 258.4K |
BLUE OWL CAPITAL HOLDINGS LP pharmaceutical preparations | 550.0K | 1.53% | 1.53% | $3.85B | Nov 12, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 513.7K | 1.43% | 1.43% | $3.60B | Nov 12, 2025 | ▲ 283.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
21
Increased
+13.37M shares22
New Positions
first time holders5
Decreased
−344.6K shares0
Sold Out
fully exitedNet shares change (top 50)
+13.02M
+13.37M / −344.6K
Net new holders
+38
22 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IMRX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
14
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Neufeld Leah R CHIEF PEOPLE OFFICER | Mar 13, 2026 | Award | 3,628 | $4.29 | $15.6K | 29.6K | Form 4 ↗ |
Bookman Michael CHIEF LEGAL OFFICER, SECRETARY | Feb 3, 2026 | Award | 176,000 | $4.91 | $864.2K | 176.0K | Form 4 ↗ |
Brakewood Harold Eugene Chief Business Officer | Feb 3, 2026 | Award | 140,000 | $4.91 | $687.4K | 140.0K | Form 4 ↗ |
Hall Brett Matthew CHIEF SCIENTIFIC OFFICER | Feb 3, 2026 | Award | 344,000 | $4.91 | $1.69M | 344.0K | Form 4 ↗ |
Matushansky Igor Chief Medical Officer | Feb 3, 2026 | Award | 140,000 | $4.91 | $687.4K | 140.0K | Form 4 ↗ |
Morales Mallory SVP Finance, CAO | Feb 3, 2026 | Award | 140,000 | $4.91 | $687.4K | 140.0K | Form 4 ↗ |
Neufeld Leah R CHIEF PEOPLE OFFICER | Feb 3, 2026 | Award | 140,000 | $4.91 | $687.4K | 140.0K | Form 4 ↗ |
Zeskind Benjamin J. PRESIDENT AND CEO | Feb 3, 2026 | Award | 688,000 | $4.91 | $3.38M | 688.0K | Form 4 ↗ |
Brakewood Harold Eugene Chief Business Officer | Jan 16, 2026 | Purchase | 5,250 | $4.76 | $25.0K | 11.1K | Form 4 ↗ |
Schall Thomas J. director | Jan 15, 2026 | Purchase | 21,645 | $4.67 | $101.0K | 74.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Immuneering Corporation (IMRX) is primarily owned by institutional investors, who hold approximately 71.9% of total shares outstanding. Company insiders own approximately 30.50%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Immuneering Corporation is FMR LLC, holding approximately 8.79 million shares — equal to 24.42% of outstanding shares — as of September 30, 2025.
A total of 69 institutional investors currently hold IMRX stock, with a combined institutional value of approximately $182,645,265 as of the most recent 13F filing period.
Frequently asked questions
IMRX ownershipImmuneering Corporation (IMRX) is primarily owned by institutional investors, who hold approximately 71.9% of shares. The largest shareholder is FMR LLC with a 24.42% stake. Company insiders hold 30.50%. Data sourced from SEC Form 13F as of September 30, 2025.